Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

BACKGROUND: Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma patients. METHODS: We conducted a phase I/II study of the EGFR inhibitor erlotinib (150 mg/day) and the mTOR inhibitor temsirol...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Wen, Patrick Y., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Norden, Andrew D., Cloughesy, Timothy F., Robins, H. Ian, Lieberman, Frank S., Gilbert, Mark R., Mehta, Minesh P., Drappatz, Jan, Groves, Morris D., Santagata, Sandro, Ligon, Azra H., Yung, W.K. Alfred, Wright, John J., Dancey, Janet, Aldape, Kenneth D., Prados, Michael D., Ligon, Keith L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2014
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956354/
https://ncbi.nlm.nih.gov/pubmed/24470557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not247
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller